arthur l. rosenthal – directordr. rosenthal is a director and member of the compensation committee for livanova plc, a uk global medical technology company. prior, dr. rosenthal served on the cyberonics board of directors as a non-executive director and chair of the compensation committee from january 2007 to october 2015. since june 2010, dr. rosenthal has served as a professor of practice in the biomedical engineering department at boston university. since december 2011, dr. rosenthal has also served as ceo of geyecue, ltd., which he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. from june 2011 until july 2012, arthur served as executive vice-chairman of cappella medical devices ltd. (now arravasc ltd.), a development-stage company focused on novel device solutions for coronary artery disease. from june 2009 until june 2011, dr. rosenthal served as president and ceo of cappella, inc. arthur served as chairman, from january 2002, and ceo, commencing in january 2005, of labcoat, ltd. until its acquisition by boston scientific corporation in december 2008. from january 1994 to may 2000, dr. rosenthal was a senior vice president, corporate officer, and chief development officer of boston scientific, and from may 2000 until his retirement in january 2005, he was a senior vice president, chief scientific officer, and executive committee member of boston scientific. from 2000 until 2010, arthur served as a non-executive director, and from 2006 through 2009, as chairman of the remuneration committee, of renovo, ltd., a u.k.-based pharmaceutical company that became publicly traded in 2006. in july 2009, arthur joined the board of interface biologics, inc., a toronto-based development stage company focused on drug delivery devices, as a non-executive director. in april 2011, dr. rosenthal was elected chairman at interface biologics, inc. from april 2013 to may 2015, dr. rosenthal served as a non-executive director and member of the compensation committee of arch technologies, inc. and is currently a member of arch’s clinical advisory board. in 2015, dr. rosenthal was appointed to the industrial advisory committee, curam (national university in galway, ireland). dr. rosenthal is a fellow of the american institute of medical and biological engineering since 2003.